180 related articles for article (PubMed ID: 33070648)
1. Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?
Deligiorgi MV; Panayiotidis MI; Trafalis DT
Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1235-1252. PubMed ID: 33070648
[TBL] [Abstract][Full Text] [Related]
2. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
[TBL] [Abstract][Full Text] [Related]
4. Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective.
Deligiorgi MV; Trafalis DT
Expert Opin Biol Ther; 2020 Nov; 20(11):1331-1346. PubMed ID: 32658547
[TBL] [Abstract][Full Text] [Related]
5. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos J; Singer C; Narod SA
Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
[TBL] [Abstract][Full Text] [Related]
6. Denosumab for treatment of breast cancer bone metastases and beyond.
Nangia JR; Ma JD; Nguyen CM; Mendes MA; Trivedi MV
Expert Opin Biol Ther; 2012 Apr; 12(4):491-501. PubMed ID: 22348344
[TBL] [Abstract][Full Text] [Related]
7. RANKL/RANK: from bone loss to the prevention of breast cancer.
Sigl V; Jones LP; Penninger JM
Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
[TBL] [Abstract][Full Text] [Related]
9. The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn.
Deligiorgi MV; Trafalis DT
Expert Opin Drug Saf; 2021 Feb; 20(2):191-213. PubMed ID: 33287586
[TBL] [Abstract][Full Text] [Related]
10. Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
Cuyàs E; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Cell Cycle; 2017 Jun; 16(11):1022-1028. PubMed ID: 28387573
[TBL] [Abstract][Full Text] [Related]
11. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
12. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
13. Denosumab in breast cancer treatment.
Drooger JC; van der Padt A; Sleijfer S; Jager A
Eur J Pharmacol; 2013 Oct; 717(1-3):12-9. PubMed ID: 23545361
[TBL] [Abstract][Full Text] [Related]
14. The RANK-RANKL axis: an opportunity for drug repurposing in cancer?
Peters S; Clézardin P; Márquez-Rodas I; Niepel D; Gedye C
Clin Transl Oncol; 2019 Aug; 21(8):977-991. PubMed ID: 30656607
[TBL] [Abstract][Full Text] [Related]
15. Denosumab for the treatment of bone metastases in advanced breast cancer.
Casas A; Llombart A; Martín M
Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
[TBL] [Abstract][Full Text] [Related]
16. The Roadmap of RANKL/RANK Pathway in Cancer.
Casimiro S; Vilhais G; Gomes I; Costa L
Cells; 2021 Aug; 10(8):. PubMed ID: 34440747
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
[TBL] [Abstract][Full Text] [Related]
18. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
19. Denosumab in breast cancer.
Lipton A
Curr Oncol Rep; 2011 Feb; 13(1):1-4. PubMed ID: 21053109
[TBL] [Abstract][Full Text] [Related]
20. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]